<table class="info">
<tr>
<th nowrap="">ClinicalTrials Identifier:</th><td>NCT02147561</td>
</tr>
<tr>
<th>Updated:</th><td>2014_05_23</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Descriptive Information</h2>
</th>
</tr>
<tr>
<th>Brief title</th><td>
<p>A Safety and Efficacy Study of BOTOX® in Korean Adults With Chronic Migraine</p>
</td>
</tr>
<tr>
<th>Official title</th><td>
<p></p>
</td>
</tr>
<tr>
<th>Brief summary</th>
</tr>
<tr>
<td class="bigdent" colspan="2">
<p>This study will evaluate the safety and efficacy of BOTOX® treatment in Korean adults with chronic migraine.</p>
</td>
</tr>
<tr>
<th>Detailed description</th>
</tr>
<tr>
<td class="bigdent" colspan="2">
<p></p>
</td>
</tr>
<tr>
<th>Phase</th><td>Phase 4</td>
</tr>
<tr>
<th>Study type</th><td>Interventional</td>
</tr>
<tr>
<th>Study design</th><td>Treatment</td>
</tr>
<tr>
<th>Study design</th><td>Open Label</td>
</tr>
<tr>
<th>Study design</th><td>Single Group Assignment</td>
</tr>
<tr>
<th>Study design</th><td>Safety/Efficacy Study</td>
</tr>
<tr>
<th>Primary outcome</th><td>Measure: Percentage of Patients with Adverse Events<br/>Time Frame: 28 Days<br/>Safety Issue? No</td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: Change from Baseline in Headache Impact Test-6 (HIT-6) Total Score<br/>Time Frame: Baseline, Day 28<br/>Safety Issue? No</td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: Physician Global Assessment of Outcome on a 3-Point Scale<br/>Time Frame: Day 28<br/>Safety Issue? No</td>
</tr>
<tr>
<th>Condition</th><td>
         Migraine Disorders
      </td>
</tr>
<tr>
<th>Arm/Group</th><td>
<div>Arm Label: botulinum toxin Type A      
                   
        Experimental</div>
<p>Botulinum toxin Type A injected across specific head and neck muscles on Day 0.</p>
</td>
</tr>
<tr>
<th>Intervention</th><td>
<div>Biological/Vaccine: botulinum toxin Type A
                   
            Arm Label: botulinum toxin Type A</div>
<p>Botulinum toxin Type A injected across specific head and neck muscles on Day 0.</p>
</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Recruitment Information</h2>
</th>
</tr>
<tr>
<th>Status</th><td>Not yet recruiting</td>
</tr>
<tr>
<th>Start date</th><td>
         2014-06
      </td>
</tr>
<tr>
<th>Last follow-up date</th><td>
         2015-01
      
      (Anticipated)
  </td>
</tr>
<tr>
<th>Primary completion date</th><td>
         2015-01
      
      (Anticipated)
  </td>
</tr>
<tr>
<th>Criteria</th>
</tr>
<tr>
<td class="bigdent" colspan="2">
<p>Inclusion Criteria:<br/>                - Ethnically Korean with a diagnosis of chronic migraine<br/>
<br/>                Exclusion Criteria:<br/>                - Anticipated need for botulinum toxin treatment for any reason other than chronic migraine during the study<br/>                - Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis</p>
</td>
</tr>
<tr>
<th>Gender</th><td>
            Both
         </td>
</tr>
<tr>
<th>Minimum age</th><td>18 Years</td>
</tr>
<tr>
<th>Healthy volunteers</th><td>No</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Administrative Data</h2>
</th>
</tr>
<tr>
<th>Organization name</th><td>Allergan</td>
</tr>
<tr>
<th>Organization study ID</th><td>191622-148</td>
</tr>
<tr>
<th>Sponsor</th><td>
               Allergan
            </td>
</tr>
<tr>
<th>Health Authority</th><td>
               South Korea: Korea Food and Drug Administration (KFDA)
         </td>
</tr>
</table>